SCHEMBL3883907

SCHEMBL3883907

Cn1ncc2cc(-c3cc(CCC(=O)O)cc(N)c3OC3CCCC3)ccc21

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44
FFAR4 Q5NUL3 1/20 0.41
AR P10275 6/20 0.41
CCNC P24863 3/20 0.39
CDK8 P49336 3/20 0.39
USP7 Q93009 1/20 0.38
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
RXRG P48443 1/20 0.37
USP30 Q70CQ3 1/20 0.36
S1PR1 P21453 1/20 0.36
CTSC P53634 1/20 0.36
PDE1C Q14123 1/20 0.36
LRRK2 Q5S007 1/20 0.36
KDM1A O60341 1/20 0.36
JAK3 P52333 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3881782 0.99 THRA (0.46) THRATHRBFFAR4ARCCNC
SCHEMBL3686310 0.91 AR (0.40) ARCCNCCDK8USP7USP30
SCHEMBL3682581 0.91 THRA (0.46) THRATHRBFFAR4ARCCNC
SCHEMBL3887605 0.90 THRA (0.43) THRATHRBFFAR4RXRARXRB
SCHEMBL3880452 0.89 THRA (0.44) THRATHRBFFAR4ARCCNC
Ak-106 SCHEMBL29359236 0.89 AR (0.43) FFAR4ARCCNCCDK8USP7
Ak-106 SCHEMBL924434 0.89 AR (0.43) FFAR4ARCCNCCDK8USP7
SCHEMBL3881177 0.89 THRA (0.45) THRATHRBFFAR4RXRARXRB
SCHEMBL3889221 0.89 THRA (0.46) THRATHRBFFAR4ARCCNC
SCHEMBL925771 0.88 AR (0.39) ARCCNCCDK8USP7USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP claimed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 THRA 1720/4885THRB 3187/4885FFAR4 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.